The trajectory of companies tied to Sildenafil's legacy presents a challenging investment landscape. While the initial success generated substantial gains, generic alternatives have significantly diminished sales . Investing in associated pharmaceutical companies now requires a careful assessment of proprietary rights , evolving medical shifts , an